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Summary
Background Hydroxychloroquine has been shown to inhibit entry of severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) into epithelial cells in vitro, but clinical studies found no evidence of reduced mortality when treating 
patients with COVID-19. We aimed to evaluate the effectiveness of hydroxychloroquine for prevention of COVID-19 
mortality, as opposed to treatment for the disease.
Methods We did a prespecified observational, population-based cohort study using national primary care data and 
linked death registrations in the OpenSAFELY platform, which covers approximately 40% of the general population 
in England, UK. We included all adults aged 18 years and older registered with a general practice for 1 year or more 
on March 1, 2020. We used Cox regression to estimate the association between ongoing routine hydroxychloroquine 
use before the COVID-19 outbreak in England (considered as March 1, 2020) compared with non-users of 
hydroxychloroquine and risk of COVID-19 mortality among people with rheumatoid arthritis or systemic lupus 
erythematosus. Model adjustment was informed by a directed acyclic graph.
Findings Between Sept 1, 2019, and March 1, 2020, of 194 637 people with rheumatoid arthritis or systemic lupus 
erythematosus, 30 569 (15·7%) received two or more prescriptions of hydroxychloroquine. Between March 1 and 
July 13, 2020, there were 547 COVID-19 deaths, 70 among hydroxychloroquine users. Estimated standardised 
cumulative COVID-19 mortality was 0·23% (95% CI 0·18 to 0·29) among users and 0·22% (0·20 to 0·25) among 
non-users; an absolute difference of 0·008% (–0·051 to 0·066). After accounting for age, sex, ethnicity, use of other 
immunosuppressive drugs, and geographical region, no association with COVID-19 mortality was observed (HR 1·03, 
95% CI 0·80 to 1·33). We found no evidence of interactions with age or other immunosuppressive drugs. Quantitative 
bias analyses indicated that our observed associations were robust to missing information for additional biologic 
treatments for rheumatological disease. We observed similar associations with the negative control outcome of 
non-COVID-19 mortality.
Interpretation We found no evidence of a difference in COVID-19 mortality among people who received 
hydroxychloroquine for treatment of rheumatological disease before the COVID-19 outbreak in England. Therefore, 
completion of randomised trials investigating pre-exposure prophylactic use of hydroxychloroquine for prevention of 
severe outcomes from COVID-19 are warranted.
Funding Medical Research Council.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Hydroxychloroquine, a commonly used conventional syn­
thetic disease­modifying antirheumatic drug (DMARD), 
is indicated for treatment of rheumatoid arthritis and 
systemic lupus erythematosus.1 Early in the severe acute 
respiratory syndrome coronavirus 2 (SARS­CoV­2) pan­
demic, it was suggested that hydroxychloroquine might 
have benefits for the treatment and prevention of 
COVID­19.2,3 Hydroxychloroquine has since been investi­
gated in several clinical trials4–9 and observational cohorts10–12 
with no evidence of therapeutic efficacy in the treatment of 
patients who are admitted to hospital with symptomatic 
COVID­19.
Evaluations of the effectiveness of pre­exposure or 
post­exposure prophylactic use of hydroxychloroquine 
for prevention, as opposed to treatment, of SARS­CoV­2 
infection or severe COVID­19 outcomes are scarce.13 One 
randomised, controlled trial examining hydroxychloro­
quine as post­exposure prophylaxis did not show signi­
ficant benefit in preventing SARS­CoV­2 infection, 
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although uncertainty in results could not exclude a possible 
benefit.14 Other trials of pre­exposure or post­exposure 
use of hydroxychloroquine for the preven tion of severe 
COVID­19 outcomes are ongoing.4 In this large, population­
based cohort study, we aimed to investi gate whether 
ongoing routine hydroxychloroquine use in the 6 months 
before March 1, 2020, considered as the start of the outbreak 
in England, UK (ie, analogous to pre­exposure prophylaxis) 
was associated with lower risk of COVID­19 mortality.
Methods
Study design and participants
We did an observational cohort study using electronic 
health record data from primary care practices using 
The Phoenix Partnership software linked to the UK’s 
Office for National Statistics death registra tions through 
OpenSAFELY. OpenSAFELY is a data analytics platform 
developed during the COVID­19 pandemic to allow near 
real­time analysis of pseudonymised primary care records 
at scale, covering approximately 40% of the population in 
England, operating within the elec tronic health record 
vendor’s highly secure data centre.15,16 Pseudonymised 
structured data include demographics, medications 
prescribed from primary care, diagnoses, and laboratory 
measures. Details on information governance of the 
OpenSAFELY platform can be found in the appendix (p 2).
We included all adults aged 18 years and older registered 
with a general practice for 1 year or more on March 1, 2020 
(index date), with information on age, sex, and deprivation. 
Within this source population, we identified people with 
one or more Read diagnostic codes17 for rheumatoid 
arthritis or systemic lupus erythematosus 6 months or 
more before the index date and who therefore had an 
indica tion for hydroxychloroquine use. Detailed informa­
tion on the Read codes used for rheumatoid arthritis and 
sys temic lupus erythematosus is available online. We 
studied people with these conditions to minimise the 
potential for confounding by indication when estimating 
the effective ness of hydroxychloroquine use rather than 
investigating how to prevent severe COVID­19 in this 
population.
This study was approved by the Health Research 
Authority (REC 20/LO/0651) and by the London School of 
Hygiene & Tropical Medicine Ethics Board (number 
21863). Participant consent was not required.
Procedures
The exposure of interest was regular use of hydroxy chlo­
roquine (≥2 prescriptions in the 6 months before the 
index date, termed users) compared with no regular use of 
hydroxychloroquine regardless of any other medication 
use (termed non­users). The primary outcome was 
Research in context
Evidence before this study
Published trials and observational studies to date have shown no 
evidence of a benefit of hydroxychloroquine as a treatment for 
patients admitted to hospital who already have COVID-19. 
A separate question remains as to whether routine ongoing use 
of hydroxychloroquine in people without COVID-19 protects 
against new infections or severe outcomes. We searched 
MEDLINE and PubMed on Sept 3, 2020, for pharmaco-
epidemiological studies evaluating hydroxychloroquine for 
prevention of severe COVID-19 outcomes. The keywords 
“hydroxychloroquine AND (COVID OR coronavirus OR 
SARS-CoV-2) AND (prophyl* OR prevent*) AND (rate OR hazard 
OR odds OR risk)” were used and results were filtered to articles 
published since Sept 3, 2019, in English, with abstracts available. 
109 papers were identified for screening; none investigated 
pre-exposure prophylactic use of hydroxychloroquine for 
prevention of severe COVID-19 outcomes. Clinical trials of 
prophylactic use of hydroxychloroquine are ongoing; however, 
the largest trial does not expect to meet recruitment targets due 
to “unjustified extrapolation and exaggerated safety concerns 
together with intense politicisation and negative publicity.” In the 
absence of reported clinical trials, evidence can be generated from 
real-world data to support the need for randomised clinical trials.
Added value of this study
In this population-based cohort study, which uses a database 
that includes around 40% of the population of England, UK, we 
investigated whether routine use of hydroxychloroquine before 
the COVID-19 outbreak (ie, pre-exposure prophylaxis) 
prevented COVID-19 mortality. With use of robust 
pharmaco-epidemiological methods, we found no evidence to 
support a substantial benefit of hydroxychloroquine in 
preventing COVID-19 mortality. At the same time, we have 
shown no evidence of harm. The absence of clear harms or 
benefits supports clinical equipoise to justify continuing 
randomised trials. We have shown in this study that it is 
feasible to address specific hypotheses about medicines in a 
rapid and transparent manner to inform interim clinical 
decision making and support the need for large-scale, 
randomised trial data.
Implications of all the available evidence
This is the first study, to our knowledge, to investigate the 
ongoing routine use of hydroxychloroquine and risk of 
COVID-19 mortality in a general population. Although we 
found no evidence of any protective benefit, due to the 
observational nature of the study, residual confounding 
remains a possibility. Completion of trials for prevention of 
severe outcomes is warranted, but before the completion 
of these, we found no evidence to support the use of 
hydroxychloroquine for prevention of COVID-19 mortality.
For Read codes see 
https://codelists.opensafely.org
See online for appendix
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COVID­19 mortality, defined by the presence of 
International Classification of Diseases­10 codes U07.1 
(COVID­19, virus identified) or U07.2 (COVID­19, virus 
not identified) on the death certificate.18 We followed­up 
participants from index date until date of death, or 7 days 
before the last date of availability of Office for National 
Statistics mortality data to account for report ing lag, 
which ever came first. People not exposed to hydroxy­
chloro quine before the index date were censored if 
prescribed it during follow­up (<2% of non­users).
Potential determinants of regular hydroxychloroquine 
use and COVID­19 mortality were identified by reviewing 
existing literature and through discussions with clini cians. 
As this research was a study of prevalent hydroxy­
chloroquine users, we included determinants that might 
have influenced the initial choice of treatment and whether 
people remained on treatment. The full list of prespecified 
variables comprised age, sex, ethnicity, index of multiple 
deprivation quintile (derived from the individual’s postcode 
at lower super output area level for a high degree of 
precision), other immunosuppressive drugs (ie, other 
conventional synthetic DMARDs, oral corticosteroids), 
smoking status, prescribed non­steroidal anti­inflamma­
tory drugs (NSAIDs), body­mass index, hypertension, 
diabetes severity as measured by diagnostic codes and 
glycated haemoglobin (HbA1c), heart dis ease, liver disease, 
respiratory disease excluding asthma, kidney disease as 
measured by estimated glomerular filtra tion rate, stroke, 
dementia, cancer, and influenza vaccina tion in the 
2019–20 season. Our methods for creating codelists have 
been previously described;16 these methods included 
clinical and epidemiological review and sign­off by at least 
two authors. Detailed information on codelists is available 
online. We developed a directed acyclic graph (DAG) to 
identify the minimal set of covariates to adjust for the 
hypothesised confounding structure, which included age, 
sex, ethnicity, geographical region, and other immuno­
suppressive drugs (appendix p 3).
Statistical analysis
Covariates were summarised with use of descriptive 
statistics, stratified by exposure status. We used Cox 
regression models with days since the index date as the 
timescale to estimate hazard ratios (HRs) and 95% CIs for 
the association between regular hydroxychloroquine use 
and COVID­19 mortality. The competing risk of death 
from causes other than COVID­19 was accounted for by 
censoring non­COVID­19 deaths, so our analysis therefore 
estimated cause­specific hazards;19 this method reflected 
our interest in establishing the effect of hydroxychloroquine 
use on COVID­19 mortality as opposed to describing 
patterns of COVID­19 mortality that might have been 
driven by the influence of hydroxychloroquine use on 
com peting events. We sequentially adjusted for sex and age 
using restricted cubic splines; for the minimal adjustment 
set informed by the DAG; and finally extended for all 
extracted covariates. Models were stratified by an indicator 
variable denoting patient population (ie, rheu ma toid 
arthritis or systemic lupus erythematosus) and geographi­
cal region. Multiple imputation (ten imputa tions) was 
used to account for missing ethnicity for 23% of the 
sample, with the imputation model including all extracted 
covariates and an indicator for the outcome. Those with 
missing body­mass index data were assumed to be non­
obese, and those with missing smoking data were assumed 
to be never­smokers (on the basis of the assumption that 
clinicians would have recorded details of obesity or 
smoking if relevant); we did not use multiple imputation 
for these variables as they are expected to be missing not at 
random in UK primary care.20 Proportional hazards were 
checked by examining the Schoenfeld residuals over time.
We generated cumulative mortality curves standard­
ised to adjust for different covariate distributions in the 
exposed group. First, a flexible parametric Royston­Parmar 
model with the same covariates as the DAG­informed Cox 
model was fitted, with the baseline hazard modelled with 
use of a three degrees­of­freedom spline. The survival 
function was predicted from this model for every individual 
Figure 1: Study diagram
End of follow-up was the date of death or 7 days before last date of the Office of National Statistics mortality data 
to account for reporting lag, or date of first hydroxychloroquine prescription on or after index date (for people 
without hydroxychloroquine use at index date), whichever came first. STP=Sustainability and Transformation 
Partnership. DMARD=disease-modifying antirheumatic drug. IMD=index of multiple deprivation. SLE=systemic 
lupus erythematosus. 
Inclusion rheumatoid
arthritis or SLE diagnosis
[–∞ to –180 days]
  Exposure assessment window
≥2 hydroxychloroquine prescriptions 
[–180 days to –1 day]
Index date (March 1, 2020)
Time
End of follow-up
Primary outcome [0 days to ∞] 
COVID-19 death
Covariate assessment window
Age, sex, ethnicity, IMD, STP region 
[0 days to 0 days]
Smoking status, hypertension, diabetes, chronic 
heart disease, liver disease, respiratory disease 
(excluding asthma), stroke, dementia, cancer 
[–∞ to –1 day]
Body–mass index [–10 years to –1 day] 
Glycated haemoglobin, serum creatinine 
[–15 months to –1 day]
Other drug exposures
Other conventional synthetic DMARD, oral 
corticosteroid, non-steroidal anti-inflammatory 
drug, influenza vaccination [–180 days to –1 day]
Exclusion <12 months registration in general practice [–365 days to –1 day]
Exclusion ≥1 chloroquine sulfate or phosphate prescriptions 
[–180 days to –1 day]
Inclusion: ≥18 years of age [0 days to 0 days]
Exclusion: missing sex or IMD [0 days to 0 days]
Secondary outcome [0 days to ∞] 
non-COVID-19 death
For codelists see https://
codelists.opensafely.org
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with regular hydroxychloroquine use and averaged (ie, 
mean taken at each day of analysis time) to produce the 
curve for the exposed group. To produce the standardised 
comparison curve, the survival functions were predicted 
and averaged again for the same individuals, but with 
exposure set to zero. Patient population was included in 
the flexible parametric model as a binary indicator variable 
because the model could not converge with both patient 
population and geographical region as stratification vari­
ables. Comparisons between Cox and Royston­Parmar 
models can be found in the appendix (p 13).
We evaluated prespecified interactions to establish 
whether the association between regular hydroxychloro­
quine use and COVID­19 mortality varied by age, exposure 
to other conventional synthetic DMARDs, oral cortico­
steroids, and NSAIDs. Two­sided p values were calculated 
from Wald tests on interaction terms.
We adjusted for ethnicity in a model excluding people 
with missing ethnicity and compared results with those 
from multiple imputation. In primary analyses, less than 
2% of the comparison group had one prescription of 
hydroxychloroquine in the 6­month exposure window. We 
redefined exposure as one or more prescriptions in the 
3 months before the index date. We compared results 
from primary models stratified for patient popula tion 
(rheuma toid arthritis or systemic lupus erythematosus) to 
a model that included patient population as a binary 
indicator variable as well as modelling each population 
separately.
We calculated bias­adjusted HRs to evaluate how adjust­
ment for biologic DMARDs, including targeted syn thetic 
DMARDs, which were not available for this analysis, might 
have produced different results under differing assump­
tions of prevalence and effect on COVID­19 mortality.21 Pre­
valence of biologic DMARDs in each expo sure group was 
estimated from pre­existing scientific literature (18% among 
users and 21% among non­users);22 however, we also 
examined more extreme values of prevalence (appendix 
pp 11–12). We assumed a range of potential associations 
between biologic DMARDs and COVID­19 mortality from 
0·8 to 1·2.
Our analyses used non­COVID­19 mortality as a negative 
control outcome, censoring at COVID­19 death. We 
hypoth esised that if associations observed in primary 
analyses were due to confounding by indication, we would 
observe a similar association with non­COVID­19 mortality.
We used Python, version 3.8 and Structured Query 
Language Server 2016, Enterprise SP2 for data manage­
ment, and Stata, version 16.1 for analysis. All code for data 
management and analyses in addition to all itera tions of 
the prespecified protocol are archived with version control.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. CTR, CEM, CB, AJW, and JC had full access to 
all of the data and the corresponding author had final 
responsibility for the decision to submit for publication.
Results
The study design is shown in figure 1. We identified 
194 637 people who were first diagnosed with rheuma­
toid arthritis or systemic lupus erythematosus at least 
6 months before March 1, 2020 (ie, index date), for analysis 
(figure 2). Of these, 30 569 (15·7%) individuals received 
two or more prescriptions of hydroxychloroquine in the 
6 months before the index date (median number of 
prescriptions 5, IQR 3–6), showing regular use. Although 
exposure was ascertained in the 6 months before the index 
date, 29 707 (97·2%) users received their first hydroxy­
chloroquine prescription before this exposure window and 
27 131 (88·8%) initiated 1 or more years before. Hydroxy­
chloroquine users were younger (median age 63 years 
[IQR 53–72] for users, 66 years [55–76] for non­users) and 
more likely to be women (76·3% of users were women; 
70·2% of non­users were women); other demographic 
characteristics between exposure groups were broadly 
similar (table). Hydroxychloroquine users were more likely 
to be taking other conventional synthetic DMARDs (51·5% 
vs 34·0%), oral corticosteroids (22·5% vs 16·3%), and 
NSAIDs (21·8% vs 16·3%) than non­users. Distributions 
of characteristics in rheumatoid arthritis and systemic 
lupus erythematosus populations are shown in the 
appendix (pp 5–8).
Figure 2: Study profile
SLE=systemic lupus erythematosus. *Including sex and index of multiple 
deprivation. 
21 687 524 people registered with a general practice on 
March 1, 2020, with at least 1 year of follow-up
17 463 543 adults aged 18 years or older
17 235 400 eligible source population
194 658 eligible cohort
194 637 people included in primary analyses
4 223 981 aged <18 years
228 143 missing demographics*
17 040 742 no diagnosis of rheumatoid 
arthritis or SLE before            
Sept 1, 2019
21 one or more prescriptions to 
chloroquine sulfate or 
phosphate in exposure window
For the code and protocol see 
https://github.com/opensafely/
hydroxychloroquine-research
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Between March 1 and July 13, 2020, there were 
547 COVID­19 deaths among people with rheumatoid 
arthritis or systemic lupus erythematosus, 70 of which 
were among regular users of hydroxychloroquine. Esti­
mated standardised cumulative mortality was 0·23% 
(95% CI 0·18–0·29) among users and 0·22% (0·20–0·25) 
among non­users at the end of follow­up (figure 3). 
The abso lute cumulative risk difference was 0·008% 
(95% CI –0·051 to 0·066). In unadjusted analyses, regular 
users of hydroxychloroquine had a decreased risk of 
COVID­19 mortality (HR 0·78, 95% CI 0·60–1·00, 
figure 4). After adjusting for age and sex, there was no 
longer any evidence of association (HR 1·08, 0·84–1·40). 
Additionally, adjusting for variables identified in the DAG 
(HR 1·03, 0·80–1·33) or extending to all covariates 
(HR 1·03, 0·80–1·33) did not alter conclusions. There 
was no evi dence of interaction by age, exposure to other 
conven tional synthetic DMARDs, oral corticosteroids, or 
NSAIDs (appendix p 9). When analysing rheumatoid 
arthritis and systemic lupus erythematosus populations 
separately, we continued to see no clear effect of hydroxy­
chloroquine use (appendix p 4).
Results from all sensitivity analyses provided similar 
findings to primary analyses (appendix p 10). In quanti­
tative bias analyses, values of the bias­adjusted association 
ranged from HR 0·97 (95% CI 0·75–1·26) to HR 1·09 
(0·84–1·40; appendix p 12). Hydroxychloroquine use 
was not associated with the negative control outcome of 
non­COVID­19 mortality after adjustment for age and sex 
(HR 1·00, 95% CI 0·87–1·15; figures 3, 4).
Discussion
In this national, population­based study of hydroxy­
chloroquine users, we found no evidence that pre­
exposure use of hydroxychloroquine was associated with 
either a beneficial or harmful effect on COVID­19 
mortality. The CIs around the relative risk suggest that we 
could exclude substantial benefit, though a modest 
benefit or harm on a relative scale could not be ruled out. 
However, even if hydroxychloroquine provided a benefit, 
our results showed a maximum absolute risk reduction of 
0·05% in the context of an absolute risk of 0·22% of 
COVID­19 mortality among non­users. If there were 
substantial differences in health status between the 
exposure groups, then we would have anticipated to see 
those differences reflected in analyses of non­COVID­19 
mortality. We found no association with this outcome, 
seen as a negative control. Taken together, our findings do 
not provide any strong support for a major protective 
effect from ongoing routine hydroxychloroquine use, as 
has been previously hypoth esised.2,3 Our estimates were 
robust to multiple sensitivity analyses. We showed that it 
is feasible to address specific hypotheses about medicines 
in a transparent manner in response to speculation, 
using OpenSAFELY, and to inform regulatory bodies 
decision making in the absence of high quality, ran­
domised trial data. However, due to the observational 
nature of the study, a degree of uncertainty persists 
that can only be addressed through large­scale random­
ised trials.
No 
hydroxychloroquine 
(n=164 068)
Hydroxychloroquine 
(n=30 569)
Total  
(n=194 637)
Rheumatoid arthritis 144 151 (87·9%) 23 723 (77·6%) 167 874 (86·2%)
Systemic lupus erythematosus 19 917 (12·1%) 6846 (22·4%) 26 763 (13·8%)
Age, years
Median (IQR) 66 (55–76) 63 (53–72) 66 (54–75)
18–39 11 433 (7·0%) 2276 (7·4%) 13 709 (7·0%)
40–49 15 829 (9·6%) 3609 (11·8%) 19 438 (10·0%)
50–59 30 457 (18·6%) 6629 (21·7%) 37 086 (19·1%)
60–69 37 726 (23·0%) 7973 (26·1%) 45 699 (23·5%)
70–79 42 090 (25·7%) 7148 (23·4%) 49 238 (25·3%)
≥80 26 533 (16·2%) 2934 (9·6%) 29 467 (15·1%)
Sex
Women 115 106 (70·2%) 23 334 (76·3%) 138 440 (71·1%)
Men 48 962 (29·8%) 7235 (23·7%) 56 197 (28·9%)
Ethnicity
White 112 367 (68·5%) 20 330 (66·5%) 132 697 (68·2%)
South Asian 8502 (5·2%) 1996 (6·5%) 10 498 (5·4%)
Black 2425 (1·5%) 572 (1·9%) 2997 (1·5%)
Mixed 1005 (0·6%) 274 (0·9%) 1279 (0·7%)
Other 1508 (0·9%) 330 (1·1%) 1838 (0·9%)
Missing 38 261 (23·3%) 7067 (23·1%) 45 328 (23·3%)
Index of multiple deprivation
1 (least deprived) 32 954 (20·1%) 6014 (19·7%) 38 968 (20·0%)
2 33 351 (20·3%) 6086 (19·9%) 39 437 (20·3%)
3 32 800 (20·0%) 6142 (20·1%) 38 942 (20·0%)
4 32 402 (19·7%) 6075 (19·9%) 38 477 (19·8%)
5 (most deprived) 32 561 (19·8%) 6252 (20·5%) 38 813 (19·9%)
Residence type
Rural 38 305 (23·3%) 7351 (24·0%) 45 656 (23·5%)
Urban 125 763 (76·7%) 23 218 (76·0%) 148 981 (76·5%)
Body-mass index, kg/m²
<18·5 3692 (2·3%) 680 (2·2%) 4372 (2·2%)
18·5–24·9 48 051 (29·3%) 8930 (29·2%) 56 981 (29·3%)
25·0–29·9 52 667 (32·1%) 9203 (30·1%) 61 870 (31·8%)
30·0–34·9 29 652 (18·1%) 5663 (18·5%) 35 315 (18·1%)
35·0–39·9 12 372 (7·5%) 2627 (8·6%) 14 999 (7·7%)
≥40·0 6156 (3·8%) 1571 (5·1%) 7727 (4·0%)
Missing 11 478 (7·0%) 1895 (6·2%) 13 373 (6·9%)
Smoking status
Never 62 705 (38·2%) 11 479 (37·6%) 74 184 (38·1%)
Former 77 740 (47·4%) 14 692 (48·1%) 92 432 (47·5%)
Current 23 079 (14·1%) 4332 (14·2%) 27 411 (14·1%)
Missing 544 (0·3%) 66 (0·2%) 610 (0·3%)
Diabetes
No diabetes 133 954 (81·6%) 25 876 (84·6%) 159 830 (82·1%)
Diabetes, HbA1c <7·5% 19 560 (11·9%) 3153 (10·3%) 22 713 (11·7%)
Diabetes, HbA1c ≥7·5% 7930 (4·8%) 1068 (3·5%) 8998 (4·6%)
Diabetes, missing HbA1c 2624 (1·6%) 472 (1·5%) 3096 (1·6%)
(Table continues on next page)
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Numerous randomised trials4–9 have not found any 
clinical benefit of hydroxychloroquine for treatment, as 
opposed to prevention, of COVID­19. Previous observa­
tional studies had limitations in their design and analysis,23 
including small sample sizes and focusing only on 
patients who were admitted to hospital, which might 
produce spurious associations.24 Hydroxychloroquine has 
been approved for use clinically for more than 50 years, 
and most studies of hydroxychloroquine for treatment of 
COVID­19 have not shown substantial harm. How­
ever, the RECOVERY trial showed an increased risk 
of progression to the composite secondary outcome of 
invasive mechanical ventilation or death in a prespeci fied 
secondary analysis.5 In addition, the proportion of people 
with any major cardiac arrhythmia was higher, and 
concerns about prolongation of the QTc interval have been 
raised in trials of hydroxychloroquine in combination 
with azithromycin.9
In terms of preventive use of hydroxychloroquine, a 
randomised trial examining hydroxychloroquine for post­
exposure prophylaxis did not show a significant benefit 
in preventing infection, although the findings were 
compatible with an absolute risk reduction of as much as 
7% in the context of an absolute risk of about 14% in the 
placebo group.14 As we await the reporting of ongoing 
clinical trials of pre­exposure (as opposed to post­exposure) 
prophylactic use of hydroxychloroquine, related evi­
dence of drug effectiveness among existing users can be 
generated from observational data. We found no evidence 
to support a substantial benefit of hydroxychloroquine in 
preventing COVID­19 mortality. At the same time, we 
have shown no significant harm. These findings suggest 
justification to continue trials of hydroxychloroquine for 
prevention of COVID­19 to confirm our findings from 
observational data.
The greatest strength of this study was the large source 
population with detailed longitudinal, routinely collected 
data, which enabled us to examine drug effects on an 
infrequent outcome in a disease­specific cohort. We were 
able to focus analyses on people with indications for the 
use of hydroxychloroquine, a key component to mitigate 
con founding by indication in pharmaco­epidemiological 
research of real­world data. Before starting the analy­
sis, we developed a DAG to identify a minimal set of 
covariates to adjust for the hypothesised confounding 
structure. We also fitted models adjusting for additional 
characteristics that had been suggested as potentially 
important when in consultation with clinicians. We did 
informative sensitivity analyses including quantitative 
bias analyses to test key assumptions about missing data 
for biologic DMARD treatments. Lastly, our population 
included regular users of hydroxychloroquine, who were 
No 
hydroxychloroquine 
(n=164 068)
Hydroxychloroquine 
(n=30 569)
Total (n=194 637)
(Continued from previous page)
eGFR, mL/min per 1·73m²
≥60 109 606 (66·8%) 23 765 (77·7%) 133 371 (68·5%)
30–59 21 153 (12·9%) 3375 (11·0%) 24 528 (12·6%)
<30 1698 (1·0%) 246 (0·8%) 1944 (1·0%)
Missing 31 611 (19·3%) 3183 (10·4%) 34 794 (17·9%)
Heart disease 26 292 (16·0%) 4317 (14·1%) 30 609 (15·7%)
Liver disease 2227 (1·4%) 491 (1·6%) 2718 (1·4%)
Respiratory disease (excluding 
asthma)
22 159 (13·5%) 4521 (14·8%) 26 680 (13·7%)
Neurological condition 11 003 (6·7%) 1715 (5·6%) 12 718 (6·5%)
Hypertension 71 117 (43·3%) 12 287 (40·2%) 83 404 (42·9%)
Cancer 17 144 (10·4%) 2884 (9·4%) 20 028 (10·3%)
Immunosuppression 2399 (1·5%) 570 (1·9%) 2969 (1·5%)
Influenza vaccination in the 
2019–20 season
101 112 (61·6%) 21 183 (69·3%) 122 295 (62·8%)
Other medications
Other conventional synthetic 
DMARD
55 780 (34·0%) 15 743 (51·5%) 71 523 (36·7%)
Azithromycin 751 (0·5%) 197 (0·6%) 948 (0·5%)
Oral corticosteroid 26 792 (16·3%) 6885 (22·5%) 33 677 (17·3%)
Non-steroidal anti-
inflammatory drug
26 686 (16·3%) 6670 (21·8%) 33 356 (17·1%)
Data are n (%), unless specified. HbA1c=glycated haemoglobin. eGFR=estimated glomerular filtration rate. 
DMARD=disease-modifying antirheumatic drug.
Table: Baseline characteristics
Figure 3: Cumulative mortality by hydroxychloroquine use among people 
with rheumatoid arthritis or systemic lupus erythematosus
(A) Time to COVID-19 death in ONS data and (B) time to non-COVID-19 death in 
ONS data. Outcome counts were 70 of 547 deaths among hydroxychloroquine 
users for COVID-19 mortality and 234 of 2003 deaths among hydroxychloroquine 
users for non-COVID-19 mortality. ONS=Office for National Statistics. 
0 20 40 60 80 100 120 140 160
0
0·1
0·2
0·3
0·4
0·5
0·6
0·7
0·8
0·9
1·0
B
Cu
m
ul
at
iv
e 
m
or
ta
lit
y 
(%
)
0
0·1
0·2
0·3
0·4
0·5
0·6
0·7
0·8
0·9
1·0
A
Cu
m
ul
at
iv
e 
m
or
ta
lit
y 
(%
)
Days since March 1, 2020
No hydroxychloroquine
Hydroxychloroquine
Articles
www.thelancet.com/rheumatology   Published online November 5, 2020   https://doi.org/10.1016/S2665-9913(20)30378-7 7
prescribed doses routinely used in clinical practice, with 
clarity that hydroxychloroquine administration occurred 
before exposure to SARS­CoV­2. The optimal timing25 
and dose26 of hydroxychloroquine for therapeutic and 
prophylactic use for COVID­19 has been debated. The 
standard dose of hydroxychloroquine in clinical use in 
England is 200 mg per day or 400 mg per day, commenced 
without loading dose. This dose is similar to the 200 mg 
per day used in the COPCOV trial (NCT04303507). A 
majority (97·2%) of hydroxychloroquine users in our 
cohort received their first prescription before this 
exposure window (88·8% initiated ≥1 year before), so we 
would antici pate that the vast majority of included people 
were at drug dosages similar or higher than those in 
clinical trials. Finally, we prespecified our study protocol 
and have shared all analytical code.
We also recognise possible limitations. One limitation is 
the risk of residual confounding by use of medications not 
prescribed in general practice, namely biologic DMARDs. 
Although most prescriptions in England are supplied by 
general practitioners in primary care, some medicines, 
including biologics, might be supplied by hospitals for 
various reasons, including cost. We have advocated for 
these data to be more widely shared but, at present, they 
are not available.27 Although nationwide information on 
the prevalence of concomitant use of biologic DMARDs 
and hydroxychloroquine over time were unavailable, we 
showed that our results were robust to a wide range of 
plausible assumptions about the use of these drugs and 
their potential relationship with COVID­19 mortality in 
quantitative bias analysis. A further source of confounding 
is potential misclassification of rheuma tological disease 
from Read codes, particularly among those not receiving 
DMARDs who might have less severe disease. In addition, 
we were unable to capture severity of rheumatological 
disease. However, the addition of several chronic comor­
bidities and proxies for health status in extended 
adjustment did not alter our findings. Another important 
consideration is the potential for exposure misclassi­
fication. As with any observational study that uses 
prescription data, we were unable to capture whether or 
how people took their medication. If individuals with 
prescriptions were taking their medication as directed,28 
our estimates could poten tially be biased toward null 
findings.29 However, we defined exposure based on repeat 
prescriptions, which is likely to be a good reflection of 
compliance. We also accounted for people initiating 
hydroxychloroquine after the index date by censoring 
observation time at first prescription of hydroxychloroquine 
(<2% of non­users). In some reportedly rare cases in 
March, 2020, local shortages of hydroxychloroquine might 
have occurred due to inappropriate stockpiling; however, 
the UK has not had major shortages during the COVID­19 
outbreak.30 People who were more severely immuno­
suppressed and who had a larger number of comorbidities 
might have been more likely to shield or adopt stringent 
physical distancing measures. Although we did not have a 
direct measure of shielding, there is no evidence to 
assume it would affect people with rheumatoid arthritis or 
systemic lupus erythematosus differentially by hydroxy­
chloroquine exposure. In addition, we were able to adjust 
for oral corticosteroid use, other conventional synthetic 
DMARDs, and comorbidities in the analysis. Finally, 
COVID­19 mortality as an outcome reflects the risk of 
exposure to and acquiring SARS­CoV­2 infection, as well 
as the risk of developing severe disease and subsequent 
death. We were not able to explore the risk of SARS­CoV­2 
infection in this study due to the absence of complete or 
representative testing data. However, if hydroxychloroquine 
had a strong protective effect on the risk of SARS­CoV­2 
infection, we would have expected to see this effect 
reflected in lower risk of COVID­19 mortality.
We studied a large number of people who were 
prescribed hydroxychloroquine for its licensed purpose 
and followed them up to look for clear signals of benefit in 
mortality from COVID­19 and other causes. We found no 
evidence of benefit after adjusting for important differ­
ences in those who had received hydroxychloroquine 
compared with those who were not prescribed hydroxy­
chloroquine. Completion of randomised trials for preven­
tion of severe outcomes is warranted to support these 
observational findings. The use of hydroxychloroquine for 
prevention of COVID­19 mortality outside trial settings is 
currently not justified.
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